The resulting stromal modifications (increased vessel stability and matrix degradation) are compatible with tumor expansion, stimulated simultaneously by CAFs release of tumor-supportive growth factors, including HGF, EGF, IL-6 and SDF1 [88]. The gene discussed is CXCL12; the disease is neoplasm.